Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension st
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024. Company Presentation Details:Date: Tuesday, April 16, 2024Time: 9:30 AM Eastern TimeWebcast: Register herePresenters: Ian Mortimer, President and Chief Executive Officer A live webcast of the company present
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024. Company Fireside Chat Presentation Details: Date:Thursday, April 11, 2024 Time:3:00 PM Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financ
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event. Company Fireside Chat Presentation Details: Date:Tuesday, March 19, 2024 Time:12:30-12:55 PM Eastern Time Webcast:Register here Presenters: Sherry Aulin, Chief Financial Officer Chris Von Seggern, Chief Commercial Officer A live webcast of the company presen
Xenon Pharmaceuticals Inc (NASDAQ:XENE), a clinical-stage biopharmaceutical company, focuses on developing therapeutics to improve the lives of patients with neurological disorders.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024. Company Fireside Chat Presentation Details: Date:Monday, March 11, 2024 Time:11:20 AM Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chie
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76. Xenon Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name […]
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Advances in Epilepsy and Depression Programs Highlighted Amid Financial Growth